# 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

> **NCT02916056** · PHASE3 · TERMINATED · sponsor: **vTv Therapeutics** · enrollment: 297 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Azeliragon 5mg

## Key facts

- **NCT ID:** NCT02916056
- **Lead sponsor:** vTv Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12
- **Primary completion:** 2018-06-01
- **Final completion:** 2018-06-01
- **Target enrollment:** 297 (ACTUAL)
- **Why stopped:** Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02916056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02916056, "2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02916056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*